Market Cap 434.56M
Revenue (ttm) 174.43M
Net Income (ttm) -138.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -79.63%
Debt to Equity Ratio 0.00
Volume 1,387,400
Avg Vol 1,503,704
Day's Range N/A - N/A
Shares Out 384.57M
Stochastic %K 17%
Beta 1.29
Analysts Sell
Price Target $1.55

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well...

Industry: Medical Devices
Sector: Healthcare
Phone: 650 266 6000
Fax: 650 871 7152
Address:
2 Tower Place, Suite 2000, South San Francisco, United States
VJLer
VJLer Feb. 22 at 9:18 PM
$LAB I'm curious to see what they are going to do with the $500.0 MM of cash they have. They reported $194.0 MM on 9/30/25 and then closed the trade sale after year end and generated another $300.0 MM or so in cash. And the blackout period for insiders trading ends 2 days after they announce. Going to be a little exciting over the next few weeks, i think.
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 2:01 PM
$LAB Current Stock Price: $1.15 Contracts to trade: $1.0 LAB Feb 20 2026 Call Entry: $0.36 Exit: $0.64 ROI: 78% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SmallStartLargeFinish
SmallStartLargeFinish Feb. 19 at 6:18 AM
$LAB this is going to reverse split and dilute at this rate
0 · Reply
GreenPond
GreenPond Feb. 15 at 8:56 PM
$LAB Besides the long-waited M&As, given so much cash at hand, will it be a good strategy to re-initiate stock repurchase program taking advantage of such low share price?
0 · Reply
Analysis001
Analysis001 Feb. 15 at 3:22 AM
$LAB Casdin is blackedout...we need to help him...otherwise we are going to see $0.92 before $2 on Feb 25th. I will be buying 1000 shares a day until Feb 24th starting Feb 17th for 6 remaining trading days. I Believe.
0 · Reply
Lussu1986
Lussu1986 Feb. 13 at 3:35 PM
$LAB Surely in a blackout period so Casdin cannot buy otherwise likley we would see some large purchases at current levels. Hoping they do a call with quarterly report to discuss strategic plan. In the meantime shares trade at about a 25% discount to cash while valuing continuing ops at zero. Experienced mgmt team that surely aim to prove themselves and have discussed criteria for potential acquistions as high potential but undervalued assets, strong margin potential, recurring rev model, attractive growing markets, enabling long term shareholder value creation. Lets see what they can do. Like the set up.
0 · Reply
peepthestamp
peepthestamp Feb. 13 at 1:15 PM
0 · Reply
Eskayes
Eskayes Feb. 13 at 12:47 AM
$LAB just a call option with no expiration date. They probably have a target in mind to acquire 1/2nd qtr of this year. Just hope it’s wildly accreative and not saddled with converts or warrants and crap
0 · Reply
Analysis001
Analysis001 Feb. 13 at 12:26 AM
$LAB Believe in Casdin. He has a plan. In Nov. he purchased a big stake. Believe. Buy.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 12 at 5:40 PM
$LAB Current Stock Price: $1.16 Contracts to trade: $1.0 LAB Feb 20 2026 Call Entry: $0.36 Exit: $0.66 ROI: 83% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on LAB
Standard BioTools Completes Sale of SomaLogic to Illumina

Jan 30, 2026, 9:09 AM EST - 24 days ago

Standard BioTools Completes Sale of SomaLogic to Illumina


Standard BioTools Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:05 PM EST - 3 months ago

Standard BioTools Reports Third Quarter 2025 Financial Results


Standard BioTools Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results


Standard BioTools Reports First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 10 months ago

Standard BioTools Reports First Quarter 2025 Financial Results


Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 9:44 PM EST - 1 year ago

Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript


Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:10 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript


Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:34 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript


Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:02 PM EDT - 1 year ago

Standard BioTools Announces Senior Leadership Changes


Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript

May 11, 2024, 12:45 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript


Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 8:44 PM EST - 2 years ago

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript


Standard BioTools Stockholders Approve Merger with SomaLogic

Jan 4, 2024, 10:23 PM EST - 2 years ago

Standard BioTools Stockholders Approve Merger with SomaLogic


VJLer
VJLer Feb. 22 at 9:18 PM
$LAB I'm curious to see what they are going to do with the $500.0 MM of cash they have. They reported $194.0 MM on 9/30/25 and then closed the trade sale after year end and generated another $300.0 MM or so in cash. And the blackout period for insiders trading ends 2 days after they announce. Going to be a little exciting over the next few weeks, i think.
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 2:01 PM
$LAB Current Stock Price: $1.15 Contracts to trade: $1.0 LAB Feb 20 2026 Call Entry: $0.36 Exit: $0.64 ROI: 78% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SmallStartLargeFinish
SmallStartLargeFinish Feb. 19 at 6:18 AM
$LAB this is going to reverse split and dilute at this rate
0 · Reply
GreenPond
GreenPond Feb. 15 at 8:56 PM
$LAB Besides the long-waited M&As, given so much cash at hand, will it be a good strategy to re-initiate stock repurchase program taking advantage of such low share price?
0 · Reply
Analysis001
Analysis001 Feb. 15 at 3:22 AM
$LAB Casdin is blackedout...we need to help him...otherwise we are going to see $0.92 before $2 on Feb 25th. I will be buying 1000 shares a day until Feb 24th starting Feb 17th for 6 remaining trading days. I Believe.
0 · Reply
Lussu1986
Lussu1986 Feb. 13 at 3:35 PM
$LAB Surely in a blackout period so Casdin cannot buy otherwise likley we would see some large purchases at current levels. Hoping they do a call with quarterly report to discuss strategic plan. In the meantime shares trade at about a 25% discount to cash while valuing continuing ops at zero. Experienced mgmt team that surely aim to prove themselves and have discussed criteria for potential acquistions as high potential but undervalued assets, strong margin potential, recurring rev model, attractive growing markets, enabling long term shareholder value creation. Lets see what they can do. Like the set up.
0 · Reply
peepthestamp
peepthestamp Feb. 13 at 1:15 PM
0 · Reply
Eskayes
Eskayes Feb. 13 at 12:47 AM
$LAB just a call option with no expiration date. They probably have a target in mind to acquire 1/2nd qtr of this year. Just hope it’s wildly accreative and not saddled with converts or warrants and crap
0 · Reply
Analysis001
Analysis001 Feb. 13 at 12:26 AM
$LAB Believe in Casdin. He has a plan. In Nov. he purchased a big stake. Believe. Buy.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 12 at 5:40 PM
$LAB Current Stock Price: $1.16 Contracts to trade: $1.0 LAB Feb 20 2026 Call Entry: $0.36 Exit: $0.66 ROI: 83% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Jkpga
Jkpga Feb. 12 at 3:38 PM
$LAB constant bleed. Only pushes up when casdin buys. Absolute garbage
0 · Reply
Wisenheimer
Wisenheimer Feb. 11 at 7:56 PM
$LAB when is the Reverse Split going to be announced?
0 · Reply
Estimize
Estimize Feb. 10 at 7:21 PM
Wall St is expecting -0.03 EPS for $LAB Q1 [Reporting 05/05 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con
0 · Reply
Wisenheimer
Wisenheimer Feb. 4 at 9:14 PM
$LAB and reverse split proposal
1 · Reply
Analysis001
Analysis001 Feb. 4 at 4:17 PM
$LAB Looking forward to the earnings call and a tender offer....late feb...validation of step 1.
0 · Reply
Analysis001
Analysis001 Feb. 4 at 6:08 AM
$LAB may be they can execute this over the next 6-12 months. Hope?
0 · Reply
Analysis001
Analysis001 Feb. 3 at 11:44 PM
$LAB : 4. The Endgame: The "Accretive Swap" (Step 2) The Strategy: Once the stock is repriced to ~$1.85+, $LAB.X uses the remaining cash + the now-more-valuable stock to acquire a private unicorn (e.g., Vizgen/Ultivue). The Magic Math: • Share Count: Stays roughly flat (Retire ~80M shares in Tender Issue ~100M shares for Merger). • Revenue: DOUBLES (Adds $100M+ high-growth revenue). • Asset: Swaps "lazy cash" for a high-growth monopoly in Spatial Biology.
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:59 PM
$LAB 3. The Tax Fix: "Pro-Rata Participation" The Alpha: Casdin (and Viking) will likely SELL into the Tender Offer proportionally. Why this is Bullish: It keeps their ownership % flat (dodging the IRS tax penalty). It lets Casdin book a quick ~40% win on the shares he bought at $1.30. It clears the way for a massive buyback that includes Retail.
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:59 PM
$LAB 2. The Resolution: The Tender Offer (Step 1) The Move: A $150M Tender Offer priced around $1.85. Why: It forces the stock price up overnight, creating a new floor. The Trap: If the company buys back shares and Casdin holds, his ownership % spikes. This triggers IRS Section 382, wiping out millions in Tax Credits (NOLs).
0 · Reply
Analysis001
Analysis001 Feb. 3 at 10:57 PM
$LAB The "Whale Swap" Blueprint – How BoD Solves the $550M Puzzle Everyone sees the cash ($550M vs $540M Market Cap). Everyone sees the accumulation by hedge funds (Casdin + MAK). But nobody is talking about HOW they unlock it without blowing up the company. Here is the "Game Theory" model for the next 6-12 months. 1. The Price Problem (Why we are stuck at $1.40) • Issue: BoD wants to build a $2B empire, but they can't buy high-growth companies using LAB stock as currency when it’s trading at $1.40. It’s too dilutive. • Constraint: BoD needs the stock at $2.00+ to make any M&A deal math work.
0 · Reply
WHO905
WHO905 Feb. 2 at 3:30 PM
$LAB The sale of SomaLogic completed earlier than estimated. This means current cash on hand is greater than the company's current Market Cap. When will the Street recognize this as a value play? Who is willing to bet that management uses the cash wisely and upcoming M&A is meaningful and good for the top and bottom lines? Hopefully the path to shareholder growth is now upon us.
1 · Reply
Estimize
Estimize Feb. 2 at 12:00 PM
Wall St is expecting -0.05 EPS for $LAB Q4 [Reporting 02/18 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con
0 · Reply